Perigon Wealth Management’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$543K Hold
5,837
0.01% 850
2026
Q1
$519K Sell
5,837
-19
-0.3% -$1.95K 0.01% 793
2025
Q4
$558K Sell
5,856
-71
-1% -$7.15K 0.01% 743
2025
Q3
$585K Sell
5,927
-27
-0.5% -$2.89K 0.01% 683
2025
Q2
$634K Sell
5,954
-12
-0.2% -$1.21K 0.01% 608
2025
Q1
$543K Buy
5,966
+64
+1% +$7.17K 0.01% 618
2024
Q4
$666K Buy
5,902
+224
+4% +$25.6K 0.02% 562
2024
Q3
$674K Sell
5,678
-27
-0.5% -$2.48K 0.02% 534
2024
Q2
$458K Sell
5,705
-303
-5% -$27.7K 0.01% 557
2024
Q1
$554K Buy
6,008
+1,503
+33% +$144K 0.02% 508
2023
Q4
$476K Buy
4,505
+1,299
+41% +$131K 0.02% 515
2023
Q3
$348K Sell
3,206
-7
-0.2% -$774 0.01% 542
2023
Q2
$347K Sell
3,213
-7
-0.2% -$787 0.01% 566
2023
Q1
$401K Sell
3,220
-11
-0.3% -$1.51K 0.02% 447
2022
Q4
$485K Sell
3,231
-5
-0.2% -$769 0.03% 395
2022
Q3
$437K Sell
3,236
-66
-2% -$10.1K 0.04% 356
2022
Q2
$492K Sell
3,302
-101
-3% -$15.4K 0.04% 338
2022
Q1
$580K Buy
+3,403
New +$572K 0.04% 328

Other funds holding BNTX

Perigon Wealth Management's BNTX Position: Q2 2026 in Review

Perigon Wealth Management held its BioNTech (BNTX) position steady in Q2 2026 at 5,837 shares worth $543K. The position accounts for 0.01% of the portfolio, ranked #850.

Perigon Wealth Management first reported a position in BNTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $674K in Q3 2024. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Perigon Wealth Management held 5,837 shares of BioNTech worth $543K as of Q2 2026.
  • Perigon Wealth Management left its BioNTech share count unchanged in Q2 2026.
  • BioNTech made up 0.01% of Perigon Wealth Management's portfolio in Q2 2026, its #850 holding.
  • Perigon Wealth Management first reported a position in BioNTech in Q1 2022 and has held it in 18 quarters since.
  • Perigon Wealth Management's BioNTech position peaked at $674K in Q3 2024.
  • 283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.